| Alternative Name: | TRANCE-R, TNFRSF 11A, ODFR, CD265 |
| |
| MW: | ~55kDa (SDS-PAGE). |
| |
| Source: | Produced in HEK 293 cells. The cysteine-rich region of human RANK (aa 29-213) is fused to the Fc portion of human IgG1. |
| |
| UniProt ID: | Q9Y6Q6 |
| |
| Concentration: | 1mg/ml after reconstitution. |
| |
| Formulation: | Lyophilized. Contains PBS. |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Associates of CAPE COD Inc.). |
| |
| Species reactivity: | Human, Mouse
|
| |
| Specificity: | Binds human and mouse RANKL. |
| |
| Applications: | ELISA
|
| |
| Application Notes: | ELISA: binds to RANKL. |
| |
| Reconstitution: | Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. Once reconstituted, it is recommended to prepare appropriate aliquots and to store them at -20°C. |
| |
| Handling: | Avoid freeze/thaw cycles. |
| |
| Scientific Background: | The receptor activator of NF-κB (RANK) is a member of the tumor necrosis factor receptor (TNF-R) family. RANK is a type I transmembrane receptor. It is 616 aa long and contains 4 cysteine-rich motifs in its extracellular domain, while its long cytoplasmic domain spans 383 aa. RANK is mainly expressed on dendritic cells. After binding its ligand RANKL, RANK interacts with TNF receptor-associated factor 1 (TRAF1), TRAF2, TRAF3, TRAF5 and TRAF6 which mediate activation of nuclear factor NF-κB and JNK. RANK-RANKL interactions promote survival of dendritic cells as well as differentiation in osteoclasts. Historical data has shown that RANK inhibits human rhsRANKL-induced survival of dendritic cells and osteoclasts. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
